Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Rahul Bhatt, Devendra Singh, Atish Prakash & Neeraj Mishra. (2015) Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s disease. Drug Delivery 22:7, pages 931-939.
Read now
Read now
Samuel Frank. (2010) Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatric Disease and Treatment 6, pages 657-665.
Read now
Read now
Articles from other publishers (34)
Daniele Urso, Veria Vacchiano, Giovanni Rizzo & Giancarlo Logroscino. 2023. Movement Disorders Emergencies. Movement Disorders Emergencies
49
84
.
Subhabrata Paul, Shreya Chakraborty, Uttpal Anand, Swarnali Dey, Samapika Nandy, Mimosa Ghorai, Suchismita Chatterjee Saha, Manoj Tukaram Patil, Ramesh Kandimalla, Jarosław Proćków & Abhijit Dey. (2021) Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects. Biomedicine & Pharmacotherapy 143, pages 112175.
Crossref
Crossref
Mahboobeh Ghasemzadeh Rahbardar & Hossein Hosseinzadeh. (2020) Effects of rosmarinic acid on nervous system disorders: an updated review. Naunyn-Schmiedeberg's Archives of Pharmacology 393:10, pages 1779-1795.
Crossref
Crossref
Malco Rossi, Nicole Farcy, Sergio E. Starkstein & Marcelo Merello. (2020) Nosology and Phenomenology of Psychosis in Movement Disorders. Movement Disorders Clinical Practice 7:2, pages 140-153.
Crossref
Crossref
Ciaran P.C. Galts, Luis E.B. Bettio, David C. Jewett, Charles C. Yang, Patricia S. Brocardo, Ana Lucia S. Rodrigues, Jonathan S. Thacker & Joana Gil-Mohapel. (2019) Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neuroscience & Biobehavioral Reviews 102, pages 56-84.
Crossref
Crossref
Christina Mo, Thibault Renoir & Anthony J. Hannan. 2019. Stress: Physiology, Biochemistry, and Pathology. Stress: Physiology, Biochemistry, and Pathology
243
278
.
Nicholas S. Caron, E. Ray Dorsey & Michael R. Hayden. (2018) Therapeutic approaches to Huntington disease: from the bench to the clinic. Nature Reviews Drug Discovery 17:10, pages 729-750.
Crossref
Crossref
Kori A. LaDonna, Christopher J. Watling, Susan L. Ray, Christine Piechowicz & Shannon L. Venance. (2016) Myotonic Dystrophy and Huntington’s Disease Care: “We Like to Think We’re Making a Difference”. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 43:5, pages 678-686.
Crossref
Crossref
Kori A. LaDonna, Wilma J. Koopman, Susan L. Ray & Shannon L. Venance. (2016) Hard to Swallow. Journal of Neuroscience Nursing 48:1, pages 42-51.
Crossref
Crossref
Kori A. LaDonna & Shannon L. Venance. (2015) Picturing the Experience of Living With Myotonic Dystrophy (DM1). Journal of Neuroscience Nursing 47:5, pages 285-295.
Crossref
Crossref
Esther T. Menze, Ahmed Esmat, Mariane G. Tadros, Ashraf B. Abdel-Naim & Amani E. Khalifa. (2015) Genistein Improves 3-NPA-Induced Memory Impairment in Ovariectomized Rats: Impact of Its Antioxidant, Anti-Inflammatory and Acetylcholinesterase Modulatory Properties. PLOS ONE 10:2, pages e0117223.
Crossref
Crossref
Samuel Frank. (2013) Treatment of Huntington’s Disease. Neurotherapeutics 11:1, pages 153-160.
Crossref
Crossref
Terence D. Sanger & Johnathon W. Mink. 2012. Swaiman's Pediatric Neurology. Swaiman's Pediatric Neurology
965
998
.
Masaki Shiota, Akira Yokomizo & Seiji Naito. (2011) Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. Free Radical Biology and Medicine 51:7, pages 1320-1328.
Crossref
Crossref
Okeanis Vaou & Samuel Frank. (2011) Managing chorea in Huntington’s disease. Neurodegenerative Disease Management 1:4, pages 295-306.
Crossref
Crossref
Angela Cummins, Julia Eggert, Rosanne Pruitt & Julianne S. Collins. (2011) Huntington disease. The Nurse Practitioner 36:2, pages 41-47.
Crossref
Crossref
Karen E. Anderson. 2011. Hyperkinetic Movement Disorders. Hyperkinetic Movement Disorders
15
24
.
A Giralt, H C Friedman, B Caneda-Ferrón, N Urbán, E Moreno, N Rubio, J Blanco, A Peterson, J M Canals & J Alberch. (2010) BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Therapy 17:10, pages 1294-1308.
Crossref
Crossref
Samuel Frank & Joseph Jankovic. (2010) Advances in the Pharmacological Management of Huntingtonʼs Disease. Drugs 70:5, pages 561-571.
Crossref
Crossref
Ina Han, YiMei You, Jeffrey H. Kordower, Scott T. Brady & Gerardo A. Morfini. (2010) Differential vulnerability of neurons in Huntington’s disease: the role of cell type-specific features. Journal of Neurochemistry.
Crossref
Crossref
Vívian Andrade Araújo Coelho, Rogério Gomes Beato, Paulo Henrique Teixeira do Prado, Francisco Eduardo Costa Cardoso & Hélio Lauar. (2009) Doença de Huntington: relato de caso com história familial negativa e atenuação das manifestações psiquiátricas com o uso de olanzapina. Revista Brasileira de Psiquiatria 31:2, pages 186-188.
Crossref
Crossref
Puneet Kumar & Anil Kumar. (2009)
Possible Neuroprotective Effect of
Withania somnifera
Root Extract Against 3-Nitropropionic Acid-Induced Behavioral, Biochemical, and Mitochondrial Dysfunction in an Animal Model of Huntington's Disease
. Journal of Medicinal Food 12:3, pages 591-600.
Crossref
Crossref
Wendy Phillips, Kathleen M. Shannon & Roger A. Barker. (2008) The current clinical management of Huntington's disease. Movement Disorders 23:11, pages 1491-1504.
Crossref
Crossref
Beverley Soltysiak, Penny Gardiner & Heather Skirton. (2008) Exploring supportive care for individuals affected by Huntington disease and their family caregivers in a community setting. Journal of Clinical Nursing 17:7b, pages 226-234.
Crossref
Crossref
Laura A. Wagner, Liliana Menalled, Alexander D. Goumeniouk, Daniela Brunner & Blair R. Leavitt. 2008. Animal and Translational Models for CNS Drug Discovery. Animal and Translational Models for CNS Drug Discovery
207
266
.
Shilpa Ramaswamy, Kathleen M. Shannon & Jeffrey H. Kordower. (2017) Huntington's Disease: Pathological Mechanisms and Therapeutic Strategies. Cell Transplantation 16:3, pages 301-312.
Crossref
Crossref
Isaac Túnez, Montserrat Feijóo, Juan A. Collado, Francisco J. Medina, José Peña, María del C. Muñoz, Ignacio Jimena, Francisco Franco, Ignacio Rueda, Jordi Muntané & Pedro Montilla. (2007) Effect of testosterone on oxidative stress and cell damage induced by 3-nitropropionic acid in striatum of ovariectomized rats. Life Sciences 80:13, pages 1221-1227.
Crossref
Crossref
Kathleen M. Shannon. (2007) TREATMENT OF CHOREA. CONTINUUM: Lifelong Learning in Neurology 13, pages 72-93.
Crossref
Crossref
D. Bozyczko-Coyne & M. Williams. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
193
228
.
Matthew T. Lorincz. (2006) Geriatric Chorea. Clinics in Geriatric Medicine 22:4, pages 879-897.
Crossref
Crossref
Puneet Kumar, Satyanaryana Sreenivasulu Padi, Pattipati Sreenivasulu Naidu & Anil Kumar. (2006) Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behavioural Pharmacology 17:5-6, pages 485-492.
Crossref
Crossref
Jeremy M. Van Raamsdonk, Jacqueline Pearson, Daniel A. Rogers, Ge Lu, Vilte E. Barakauskas, Alasdair M. Barr, William G. Honer, Michael R. Hayden & Blair R. Leavitt. (2005) Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology 196:2, pages 266-272.
Crossref
Crossref
Lynn Raymond & Blair Leavitt. 2005. Neurogenetics. Neurogenetics
351
376
.
Isaac Túnez, Pedro Montilla, M. Carmen Muñoz & René Drucker-Colín. (2004) Effect of nicotine on 3-nitropropionic acid-induced oxidative stress in synaptosomes. European Journal of Pharmacology 504:3, pages 169-175.
Crossref
Crossref